February 19, 2019 06:13 PM EST
R&D

Strike 3: Vi­cal ax­es its on­ly re­main­ing clin­i­cal pro­gram, com­plet­ing a tri­fec­ta of dis­as­ters

John Carroll

Editor & Founder

Vi­cal is once again turn­ing to the on­ly tool it ev­i­dent­ly knows how to use ex­pert­ly: the bud­get ax.

Fol­low­ing back-to-back clin­i­cal fail­ures lead­ing …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Af­ter stock slides, Am­gen ad­dress­es bone den­si­ty talk on obe­si­ty drug

Met­sera rais­es $215M for stud­ies of GLP-1 and amylin obe­si­ty drugs

Adap­ti­m­mune's sec­ond T cell re­cep­tor cell ther­a­py for rare sar­co­mas pass­es piv­otal test

New can­cer class heats up as BioN­Tech buys out Chi­na part­ner and its PD-L1/VEGF drug

J&J takes 340B fight with fed­er­al gov­ern­ment to court

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times